A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

Inclusion Criteria:

• Male or female participants ≥ 50 years of age

• Diagnosis of early or intermediate age-related macular degeneration (AMD) in thestudy eye as determined by the investigator on fundus examination

• Study eye (early/intermediate AMD eye) must have at least one high risk opticalcoherence tomography (OCT) feature (as defined by a central reading center).

• Diagnosis of neovascular AMD (nAMD) in the fellow eye as determined by theinvestigator.

• Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infectionare required prior to the start of the treatment with LNP023.

• If not received previously, vaccination against Haemophilius influenzae infectionshould be given, if available and according to local regulations.

Exclusion Criteria:

• History or current diagnosis of ECG abnormalities indicating significant safetyrisk, such as clinically significant cardiac arrhythmias, e.g., sustainedventricular tachycardia and clinically significant second or third degreeatrioventricular block (AV block) without a pacemaker.

• History of familial long QT syndrome or known family history of Torsades de Pointes

• History of stroke or myocardial infarction during the 6-month period prior toBaseline/Day 1, any current clinically significant arrhythmias, or any advancedcardiac or severe pulmonary hypertension

• History of end stage kidney disease requiring dialysis or renal transplant

• History of malignancy of any organ system

• History of solid organ or bone marrow transplantation

• History of recurrent meningitis or history of meningococcal infections despitevaccination

• History of immunodeficiency diseases, including a positive Human ImmunodeficiencyVirus test result at Screening

• Active Hepatitis B (HBV) or Hepatitis C (HCV) infection

• History of hypersensitivity to any of the study treatments or excipients or to drugsof similar chemical classes or clinically relevant sensitivity to fluorescein dye asassessed by the Investigator.

• Evidence of cRORA or exMNV in the study eye based on multimodal imaging asdetermined by the central reading center.

• Participants who have current active TB as evidenced by clinical, radiographic andlaboratory tests.